Information about Fenofibrate
Fenofibrate is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia. Fenofibrate therapy is associated with mild and transient serum aminotransferase elevations and with rare instances of acute liver injury, which can be severe and prolonged and lead to significant hepatic fibrosis.
Mechanism of action of Fenofibrate
Fenofibrate (fen" oh fye' brate) is a fibric acid derivative. Its lipid lowering activity is probably mediated by its interactions with the peroxisome proliferator activated receptor alpha (PPARα), which regulates gene expression of enzymes involved in fatty acid oxidation. These fenofibrate induced changes cause an increase in lipoprotein lipase levels which enhance clearance of triglyceride-rich lipoproteins.
Clinical use of Fenofibrate
Fenofibrate is recommended for therapy of hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia) and hypercholesterolemia (Fredrickson types IIa and IIb). Fenofibrate was approved for use in Europe in 1975 and in the United States in 1993.
Dosage and administration for Fenofibrate
Fenofibrate is available in multiple generic forms and under the brand names of Antara, Lipofen, Lofibra, TriCor and Triglide as capsules and tablets of multiple concentrations, ranging from 43 to 200 mg each. The recommended initial dosage in adults is 43 to 130 mg daily with adjustment to as high as 200 mg daily (depending upon the formulation).
Side effects of Fenofibrate
Lipid lowering medications
- Niacin (Nicotinic Acid)